Viona Pharmaceuticals Inc. Company Profile

Background

Overview

Viona Pharmaceuticals Inc. is a rapidly growing generic pharmaceutical company headquartered in Cranford, New Jersey. Established in May 2018, Viona is a wholly owned indirect subsidiary of Zydus Lifesciences Limited, a fully integrated global healthcare provider based in India. The company specializes in marketing and distributing a diverse portfolio of oral solid and topical generic pharmaceutical products in the United States. Viona is committed to providing high-quality, affordable generic medications with excellent customer service.

Mission and Vision

Viona's mission is to deliver high-quality, affordable generic products while maintaining exceptional service levels. The company's vision is to become a leading provider of generic pharmaceuticals in the U.S., ensuring accessibility to essential medications for a broad patient population.

Industry Significance

As a subsidiary of Zydus Lifesciences Limited, Viona benefits from the extensive experience and resources of its parent company, enabling it to effectively compete in the U.S. generic pharmaceutical market. The company's focus on affordability and quality addresses the growing demand for cost-effective healthcare solutions in the United States.

Key Strategic Focus

Core Objectives

• Market Expansion: Viona aims to expand its presence in the U.S. market by introducing a wide range of generic pharmaceutical products.

• Product Development: The company is dedicated to developing and launching new generic medications to meet the evolving needs of the healthcare sector.

• Customer Service Excellence: Viona emphasizes providing exceptional customer service to build strong relationships with healthcare providers and patients.

Areas of Specialization

• Oral Solid Dosage Forms: Viona offers a variety of oral solid medications, including tablets and capsules, across multiple therapeutic categories.

• Topical Products: The company markets and distributes topical pharmaceutical products, catering to various dermatological conditions.

Key Technologies Utilized

While specific technological platforms are not detailed in the available information, Viona's association with Zydus Lifesciences Limited suggests access to advanced pharmaceutical manufacturing technologies and research capabilities.

Primary Markets Targeted

Viona primarily targets the U.S. pharmaceutical market, focusing on healthcare providers, pharmacies, and patients seeking affordable generic medications.

Financials and Funding

Funding History

Viona Pharmaceuticals Inc. is a wholly owned indirect subsidiary of Zydus Lifesciences Limited, which is a publicly traded company. Specific details regarding Viona's independent funding history, total funds raised, and recent funding rounds are not publicly disclosed.

Notable Investors

As a subsidiary of Zydus Lifesciences Limited, Viona's financial backing is primarily from its parent company. Zydus Lifesciences Limited is a publicly traded entity, and its investors include institutional and individual shareholders.

Utilization of Capital

While specific details on the utilization of capital are not provided, it is reasonable to infer that funds are allocated towards:

• Product Development: Investing in the research and development of new generic medications.

• Market Expansion: Enhancing distribution networks and marketing efforts to increase market share.

• Operational Excellence: Improving manufacturing processes and customer service capabilities.

Pipeline Development

Key Pipeline Candidates

Viona has a robust pipeline of generic pharmaceutical products, with numerous medications in various stages of development. The company has been actively launching new products, including:

• Metronidazole Tablets, USP 250mg & 500mg: Launched in May 2019.

• Voriconazole Tablets 50mg & 200mg: Launched in July 2019.

• Doxycycline Hyclate Tablets, USP 100mg: Launched in September 2019.

• Memantine Hydrochloride Tablets, USP 5mg & 10mg: Launched in December 2019.

• Metformin Hydrochloride Tablets Extended-Release Tablets, USP 750mg: Launched in December 2019.

• Ranolazine Extended-Release Tablets 500mg & 1,000mg: Launched in January 2020.

• Acyclovir Ointment, USP 5%: Launched in July 2020.

• Desonide Cream 0.05%: Launched in July 2020.

• Betamethasone Dipropionate Ointment, USP 0.05%: Launched in September 2020.

• Fluocinonide Cream, USP 0.1%: Launched in September 2020.

• Nystatin Ointment, USP 100,000 units Per Gram: Launched in October 2020.

• Desoximetasone Ointment, USP 0.25%: Launched in November 2020.

• Triamterene and Hydrochlorothiazide Capsules, USP 37.5 mg/25 mg: Launched in January 2021.

• Nystatin and Triamcinolone Acetonide Ointment USP: Launched in January 2021.

• Desoximetasone Cream, USP 0.25%: Launched in January 2021.

• Acyclovir Capsules, USP 200 mg: Launched in January 2021.

• Felbamate Tablets, USP 400 mg & 600 mg: Launched in March 2021.

• Clindamycin Phosphate Topical Solution, USP 1%: Launched in March 2021.

• Doxycycline Hyclate Capsules, USP 50 mg & 100 mg: Launched in March 2022.

• Levofloxacin Tablets, USP 250 mg, 500 mg & 750 mg: Launched in April 2022.

• Adapalene and Benzoyl Peroxide Topical Gel, 0.3% / 2.5%: Launched in June 2022.

• Modafinil Tablets, USP 100 mg & 200 mg: Launched in July 2022.

• Aripiprazole Orally Disintegrating Tablets, USP 10 mg & 15 mg: Launched in August 2022.

• Zonisamide Capsules, USP 25 mg, 50 mg & 100 mg: Launched in September 2022.

• Clobetasol Propionate Lotion, 0.05%: Launched in October 2022.

• Tizanidine Tablets, USP 2 mg & 4 mg: Launched in December 2022.

• Mirtazapine Orally Disintegrating Tablets, USP 15 mg, 30 mg & 45 mg: Launched in January 2023.

• Bisoprolol Fumarate Tablets, USP 5 mg & 10 mg: Launched in February 2023.

• Acyclovir Cream, 5%: Launched in March 2023.

• Tavaborole Topical Solution, 5%: Launched in May 2023.

• Ivermectin Cream, 1%: Launched in July 2023.

• Loperamide Hydrochloride Capsules, USP 2 mg: Launched in July 2023.

• Sucralfate Tablets, USP 1 gram: Launched in July 2023.

• Febuxostat Tablets, 40 mg and 80 mg: Launched in July 2023.

• Metronidazole Topical Cream, 0.75%: Launched in August 2023.

• Acetazolamide Tablets, USP 125 mg and 250 mg: Launched in October 2023.

• Clindamycin Phosphate Gel, USP 1%: Launched in March 2024.

• Bisoprolol Fumarate and Hydrochlorothiazide, USP 2.5 mg/6.25 mg, 5 mg/6.25 mg and 10 mg/6.25 mg: Launched in April.